

Gastroenterology

Volume 167 / Issue 5

October 2024

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER

Gastroenterology



Organoids for Functional Precision Medicine in Advanced PDAC. See article by Boilève, et al, page 961 for additional information.

COMMENTARIES

821 Pouchitis: Is It Time to Think Beyond the Inflammation in the Pouch?

M. Camilleri

DIVERSITY, EQUITY, AND INCLUSION IN GI

826 Interventions to Increase Follow-Up of Abnormal Stool-Based Colorectal Cancer Screening Tests in Safety Net Settings: A Systematic Review

R. B. Issaka, A. Bell-Brown, T. Jewell, S. L. Jackson, and B. J. Weiner

MENTORING, EDUCATION, AND TRAINING CORNER

834 Training in Advanced Endoscopy: Current Status and Future Directions

S. Wani, R. Khan, P. V. Draganov, and C. M. Walsh

EDITORIALS

841 Shot Heard Around the World? Subcutaneous Infliximab as Maintenance Therapy for Inflammatory Bowel Disease

C. Mulanax and F. S. Velayos

See Hanauer SB et al on page 919.

843 Deconstructing the "Pain" Points When Considering the Impact of Brain-Gut Behavior Therapies on Irritable Bowel Syndrome

O. C. Aroniadis and L. Keefer

See Goodoory VC et al on page 934.



Video



Related article in CGH



Hot Papers From New Investigators



CME quiz



Editorial accompanies this article



Additional online content available



Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2024 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

Inflammatory Bowel Disease

919 Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

S. B. Hanauer, B. E. Sands, S. Schreiber, S. Danese, M. Kłopocka, J. Kierkuś, R. Kulynych, M. Gonciarz, A. Sołtysiak, P. Smoliński, S. Srećković, E. Valuyskikh, A. Lahat, M. Horyński, A. Gasbarrini, M. Osipenko, V. Borzan, M. Kowalski, D. Saenko, R. Sardinov, S. J. Lee, S. Kim, Y. Bae, S. Lee, S. Lee, J. H. Lee, S. Yang, J. Lee, J. Lee, J. M. Kim, G. Park, W. J. Sandborn, and J.-F. Colombel

See editorial on page 841.

CT-P13 (infliximab, an anti-tumor necrosis factor therapy) is a biologic drug injected under the skin (ie, subcutaneously). Subcutaneous CT-P13 was more effective than a placebo and well tolerated in patients with moderate to severe Crohn's disease or ulcerative colitis.

Functional GI Disease

934 Effect of Brain-Gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis

V. C. Goodoory, M. Khasawneh, E. R. Thakur, H. A. Everitt, G. D. Gudleski, J. M. Lackner, R. Moss-Morris, M. Simren, D. H. Vasant, P. Moayyedi, C. J. Black, and A. C. Ford

See editorial on page 843.

The efficacy of behavioral treatments for abdominal pain in irritable bowel syndrome was studied. Self-guided/minimal contact cognitive behavioral therapy, face-to-face multicomponent behavioral therapy, and face-to-face gut-directed hypnotherapy were better than a control intervention.

Pancreas

944 A Single-Cell Atlas of the Murine Pancreatic Ductal Tree Identifies Novel Cell Populations With Potential Implications in Pancreas Regeneration and Exocrine Pathogenesis

Á. Fernández, J. Casamitjana, A. Holguín-Horcajo, K. Coolens, L. Mularoni, L. Guo, O. Hartwig, T. Düking, N. Vidal, L. N. Strickland, L. Pasquali, J. M. Bailey-Lundberg, I. Rooman, Y. J. Wang, and M. Rovira

See editorial on page 845.

Thorough characterization of pancreatic murine ductal cells at single-cell resolution uncovers an unforeseen level of heterogeneity, highlighting the coexistence of 15 ductal populations and their putative role in exocrine pathogenesis and pancreas regeneration.

961 Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer

A. Boilève, J. Cartry, N. Goudarzi, S. Bedja, J. R. R. Mathieu, M.-A. Bani, R. Nicolle, A. Mouawia, R. Bouyakoub, C. Nicotra, M. Ngo-Camus, B. Job, K. Lipson, V. Boige, M. Valéry, A. Tarabay, P. Dartigues, L. Tselikas, T. de Baere, A. Italiano, S. Coscone, M. Gelli, E. Fernandez-de-Sevilla, M. Annereau, D. Malka, C. Smolenschi, M. Ducreux, A. Hollebecque, and F. Jaulin

In a large prospective study that aims to implement organoid-based functional precision medicine for pancreatic cancer, the authors identified, in a clinically relevant turnaround time, at least 1 putative hit in 91% of cases, with potential survival benefits.

977 Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis

C.-S. Leonhardt, C. Gustorff, U. Klaiber, S. Le Blanc, T. A. Stamm, C. S. Verbeke, G. W. Prager, and O. Strobel

Pancreatic cancer frequently recurs after surgery. This work identified all risk factors reported in the literature that lead to early recurrence and can thus help identify vulnerable patient groups.

Hepatobiliary

- 993 Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension**
 C.-P. Zhu, S.-Q. Liu, K.-Q. Wang, H.-L. Xiong, P. Aristu-Zabalza, Z. Boyer-Díaz, J.-F. Feng, S.-H. Song, C. Luo, W.-S. Chen, X. Zhang, W.-H. Dong, J. Gracia-Sancho, and W.-F. Xie

HTR1A antagonist, such as alverine, decreases portal hypertension in preclinical animals by targeting the portal vein and is expected to become a candidate for the clinical treatment of portal hypertension.

- 1008 Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)**
 V. C. Clark, C. Strange, P. Strnad, A. J. Sanchez, P. Kwo, V. M. Pereira, B. van Hoek, I. Barjaktarevic, A. G. Corsico, M. Pons, M. Goldklang, M. Gray, B. Kuhn, H. E. Vargas, J. M. Vierling, R. Vuppalachchi, M. Brantly, N. Kappe, T. Chang, T. Schluep, R. Zhou, J. Hamilton, J. San Martin, and R. Loomba

See editorial on page 847.

This study showed the potential benefit of treatment with fazirsiran in patients with alpha-1 antitrypsin deficiency-associated liver disease, which will be confirmed in a larger ongoing study.

RESEARCH LETTERS

- 1019 Urine Proteomics Profiling Identifies Novel Acute Pancreatitis Diagnostic Biomarkers in a Pediatric Population**
 V. S. Akshintala, M. G. Moore, Z. Cruz-Monserrate, J. D. Nathan, B. C. Searle, and M. Abu-El-Haija

- 1022 Comparative Assessment of Esophageal Proteomics in Eosinophilic Esophagitis Using SOMAscan**
 R. W. Winter, M. Muftah, X. Gu, S. T. Dillon, T. A. Libermann, and W. W. Chan

- 1026 Enterocyte-Derived and Catalytically Active Transglutaminase 2 in the Gut Lumen of Mice: Implications for Celiac Disease**
 M. T. Meling, L. Kleppa, H. A. Besser, C. Khosla, M. F. du Pré, and L. M. Sollid

- 1029 Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas**
 B. Y. Hsu, J. Driscoll, Human Cholangiocarcinogenesis Project, C. Tateno, A. N. Mattis, R. K. Kelley, and H. Willenbring

See editorial on page 849.

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e1 CME Exam 1: Effect of Brain-Gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis**
- e3 CME Exam 2: Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis**

CLINICAL PRACTICE UPDATES

- 1033 AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review**
S. Kothari, Y. Afshar, L. S. Friedman, and J. Ahn

GASTRO DIGEST

- 1046 Magnetically Guided Capsule Endoscopy Similar to EGD for Detecting Esophagogastric Varices in Patients With Cirrhosis**
M. Hanscom
- 1047 Seladelpar as an Alternate Second-Line Agent for Primary Biliary Cirrhosis**
N. Venkateswaran
- 1047 Novel Migratory Hepatocyte Population Contributes to Liver Regeneration in Acute Liver Injury**
H. Sutton and M. Bhat
- 1048 Defining the Role of Immune Microniches in Intestinal Effector Regulatory T-Cell Functionality**
D. Kotlarz

CORRESPONDENCE

- 1050 The OCEAN Study: Has Octreotide Quenched the Thirst for Angiodysplasia-Related Bleed?**
A. Tiwari
- 1051 Implications and Future Directions for Octreotide Use in Angiodysplasia Management**
W. Jiang, K. Yang, and H. Shi
- 1052 Reply**
L. C. M. J. Goltstein and J. P. H. Drenth
- 1053 All Fibers Are Not Created Equal**
R. Bolia
- 1053 Reply**
S. Y. So, T. C. Savidge, and R. J. Shulman
- 1054 Cannabis Hyperemesis Syndrome Recovers Completely When the Use of Cannabis or Synthetic Cannabinoids Is Permanently Discontinued—Cyclic Vomiting Syndrome Does Not**
U. Bonnet
- 1055 Comments on the AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome**
M. E. Mullins, E. Lothet, K. T. Baumgartner, and D. B. Liss
- 1056 Reply**
A. Rubio-Tapia and M. Camilleri